Mar 05, 2024 / 03:30PM GMT
Philip M. Nadeau - TD Cowen, Research Division - MD & Senior Research Analyst
Good morning, and welcome once again to TD Cowen's 44th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts, and it's my pleasure to moderate a fireside chat with Vertex, one of the bellwethers of the industry. We have with us today, David Altshuler, the Executive Vice President of Research and CSO; as well as Charles Wagner, the EVP and CFO. I guess I'll hand it to you guys to give a state of the company overview, what are the challenges? What are the strengths? And what does Vertex do over the next 12 to 24 months to create value?
David M. Altshuler - Vertex Pharmaceuticals Incorporated - Executive VP & Chief Scientific Officer
Yes, Phil, thanks for hosting. Happy to be back at the conference. We will make some forward-looking statements, so I'd encourage people to take a look at our recent SEC filings. Phil, it's an incredibly exciting and dynamic time at Vertex right now. Just think back over the last 90 days or so. We've had multiple approvals for
Vertex Pharmaceuticals Inc at TD Cowen Health Care Conference Transcript
Mar 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers